{"id":2153,"date":"2026-06-08T13:00:00","date_gmt":"2026-06-08T16:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2153"},"modified":"2026-06-08T13:00:00","modified_gmt":"2026-06-08T16:00:00","slug":"pgrss-linfoma-cutaneo-ctcl-micose-fungoide-sezary-car-t-mogamulizumab-brentuximab-vorinostat","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-linfoma-cutaneo-ctcl-micose-fungoide-sezary-car-t-mogamulizumab-brentuximab-vorinostat\/","title":{"rendered":"PGRSS linfoma cut\u00e2neo: CTCL, micose, CAR-T"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente desafiada por gestores de centros de oncologia linfoma cut\u00e2neo. Em 2026, h\u00e1 uma demanda crescente de hospitais com unidade linfoma cut\u00e2neo \u2014 CTCL Cutaneous T-Cell Lymphoma<\/strong> com micose fungoide MF<\/strong> est\u00e1gio IA-IIA early\/IIB-IVB advanced + s\u00edndrome de S\u00e9zary SS<\/strong> eritroderma+leucemia+linfadenopatia + CD30+ ALCL prim\u00e1rio cut\u00e2neo<\/strong> + lymphomatoid papulosis LyP<\/strong>, CBCL Cutaneous B-Cell Lymphoma<\/strong> prim\u00e1rio com PCFCL primary cutaneous follicle center lymphoma + PCMZL primary cutaneous marginal zone lymphoma + PCDLBCL-LT primary cutaneous diffuse large B-cell lymphoma leg-type, terapia direcionada \u00e0 pele<\/strong> com PUVA psoraleno+UVA<\/strong> + UVB-NB narrow-band 311nm<\/strong> + corticoides t\u00f3picos + mecloretamina Valchlor t\u00f3pico + bexaroteno Targretin t\u00f3pico, terapia sist\u00eamica<\/strong> com vorinostat Zolinza<\/strong> SAHA HDAC-inhibitor + romidepsin Istodax<\/strong> + bexaroteno Targretin<\/strong> RXR retinoid + interferon-\u03b1 + metotrexato baixa dose, biol\u00f3gico\/imunoterapia<\/strong> com brentuximab vedotin Adcetris<\/strong> Takeda anti-CD30 ADC R$ 35-65k\/dose \u00d7 6-8 doses para CD30+ + mogamulizumab Poteligeo<\/strong> Kyowa Kirin anti-CCR4 + alemtuzumab Campath<\/strong> anti-CD52 Lista C5, TSEBT Total Skin Electron Beam Therapy<\/strong> RT 30-36Gy + braquiterapia local, CAR-T cell<\/strong> ainda em desenvolvimento cl\u00ednico para CTCL, TMO aut\u00f3logo + alog\u00eanico<\/strong> para SS avan\u00e7ado refrat\u00e1rio com REDOME + REREME, fotoaf\u00e9rese extracorp\u00f3rea ECP<\/strong> Therakos CELLEX para SS + DLBCL refrat\u00e1rio. A consequ\u00eancia \u00e9 a urg\u00eancia de PGRSS dedicado para linfoma cut\u00e2neo<\/strong> \u2014 captura de mecloretamina Valchlor<\/strong> Helsinn t\u00f3pico Lista C5 R$ 4-8k\/tubo descarte espec\u00edfico citost\u00e1tico + bexaroteno Targretin<\/strong> Eisai oral Lista C5, brentuximab vedotin Adcetris<\/strong> Takeda ADC antibody-drug conjugate Lista C5 R$ 35-65k\/dose \u00d7 6-8 doses + cofre + cadeia fria 2-8\u00b0C + livro 344, mogamulizumab Poteligeo<\/strong> Kyowa Kirin anti-CCR4 Lista C5 R$ 25-45k\/dose, vorinostat Zolinza<\/strong> Merck HDAC-inhibitor + romidepsin Istodax<\/strong> Bristol-Myers + alemtuzumab Campath<\/strong> Sanofi-Genzyme anti-CD52 Lista C5 R$ 18-35k\/m\u00eas, fotoaf\u00e9rese extracorp\u00f3rea ECP Therakos CELLEX<\/strong> Mallinckrodt apheresis kit + 8-MOP psoraleno + UVA c\u00e2mara R$ 4-8k\/sess\u00e3o \u00d7 24-50 sess\u00f5es\/ano + livro RBI, TSEBT Total Skin Electron Beam Therapy<\/strong> Varian Clinac iX\/TrueBeam STx + filtro cont\u00ednuo el\u00e9trons + dos\u00edmetro de pele + acelerador linear, PUVA c\u00e2mara<\/strong> UVB-NB 311nm Daavlin + Waldmann UV5040 + acompanhamento dermatol\u00f3gico. A realidade \u00e9 que linfoma cut\u00e2neo produz RSS de alt\u00edssima especializa\u00e7\u00e3o. PGRSS de linfoma cut\u00e2neo \u00e9 cadeia integrada<\/strong> \u2014 come\u00e7a no diagn\u00f3stico<\/strong> (biopsia + IHC CD3\/CD4\/CD8\/CD30\/CCR4\/CD52 + flow cytometria + TCR clonalidade + estadiamento Olsen-EORTC), passa pela terapia<\/strong> (skin-directed PUVA\/UVB\/Valchlor + sist\u00eamica HDAC\/RXR + biol\u00f3gico Adcetris\/Poteligeo + ECP) e termina no acompanhamento<\/strong> (TSEBT + TMO + watch-and-wait). O conjunto soma R$ 25.000-52.000\/m\u00eas<\/strong> que muitos gestores subestimam.<\/p>\n

Para o gestor que opera ou planeja unidade linfoma cut\u00e2neo, \u00e9 fundamental considerar a complexidade desde o in\u00edcio.<\/p>\n

Os procedimentos linfoma cut\u00e2neo e os RSS espec\u00edficos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, a cadeia gera RSS espec\u00edficos.<\/p>\n\n\n\n\n\n\n\n\n\n
Procedimento<\/th>\nInsumo cr\u00edtico<\/th>\nF\u00e1rmaco<\/th>\nRisco RSS<\/th>\n<\/tr>\n<\/thead>\n
MF early stage IA-IIA<\/td>\nPUVA c\u00e2mara + UVB-NB 311nm<\/td>\nValchlor mecloretamina C5<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n
MF advanced IIB-IVB<\/td>\nECP Therakos CELLEX kit<\/td>\nBrentuximab Adcetris C5 R$ 35-65k<\/td>\nA4 + B + RAEE<\/td>\n<\/tr>\n
SS S\u00e9zary<\/td>\nApheresis ECP+8-MOP<\/td>\nMogamulizumab Poteligeo C5 R$ 25-45k<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n
ALCL CD30+<\/td>\nImunoter\u00e1pico ADC<\/td>\nBrentuximab vedotin Adcetris<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n
TSEBT total skin electron<\/td>\nVarian Clinac iX\/TrueBeam<\/td>\nRT 30-36Gy whole-skin<\/td>\nRAEE LINAC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 entre R$ 25.000-52.000\/m\u00eas<\/strong> em PGRSS dedicado de linfoma cut\u00e2neo vs R$ 9.000-20.000<\/strong> em PGRSS gen\u00e9rico subdimensionado.<\/p>\n

A skin-directed therapy + PUVA + Valchlor: o procedimento de alt\u00edssima especializa\u00e7\u00e3o<\/h2>\n

A primeira camada do desafio \u00e9 o skin-directed. Padr\u00e3o setorial inclui (a) PUVA psoraleno+UVA<\/strong> com 8-MOP methoxsalen oral 0.6mg\/kg + c\u00e2mara UVA 320-400nm Daavlin + Waldmann UV5040 R$ 60-150k equipamento; (b) UVB-NB narrow-band 311nm<\/strong> c\u00e2mara 2-3 sess\u00f5es\/semana + dose acumulada; (c) mecloretamina Valchlor<\/strong> Helsinn nitrogen mustard t\u00f3pico Lista C5 R$ 4-8k\/tubo aplica\u00e7\u00e3o di\u00e1ria paciente lifelong + descarte espec\u00edfico citost\u00e1tico; (d) bexaroteno Targretin<\/strong> Eisai gel t\u00f3pico Lista C5 + carmustine BCNU<\/strong> t\u00f3pico raro; (e) livro RBI Valchlor + bexaroteno<\/strong> com reten\u00e7\u00e3o 10 anos.<\/p>\n

Hospital com 30-100 CTCLs early \u00d7 R$ 20-50k\/ano em skin-directed = R$ 600k-5M\/ano em PUVA+UVB+Valchlor + livro RBI. Como discutimos no post sobre PGRSS de dermato oncol\u00f3gica<\/a>, Lista C5 t\u00f3pico \u00e9 estruturante.<\/p>\n

A sist\u00eamica HDAC + RXR + brentuximab + mogamulizumab: o est\u00e1gio Lista C5 sist\u00eamico<\/h2>\n

A segunda camada \u00e9 a sist\u00eamica. Padr\u00e3o setorial inclui (a) vorinostat Zolinza<\/strong> Merck SAHA HDAC-inhibitor 400mg\/dia oral Lista C5 + romidepsin Istodax<\/strong> Bristol-Myers IV; (b) bexaroteno Targretin<\/strong> Eisai oral RXR retinoid 300mg\/m\u00b2\/dia Lista C5; (c) brentuximab vedotin Adcetris<\/strong> Takeda anti-CD30 ADC R$ 35-65k\/dose \u00d7 6-8 doses para ALCL+MF CD30+; (d) mogamulizumab Poteligeo<\/strong> Kyowa Kirin anti-CCR4 R$ 25-45k\/dose \u00d7 12+ doses para SS+MF; (e) alemtuzumab Campath<\/strong> anti-CD52 + interferon-\u03b1 + metotrexato baixa dose.<\/p>\n

Hospital com 20-80 CTCLs advanced \u00d7 Adcetris\/Poteligeo R$ 35-50k\/dose \u00d7 12 doses = R$ 8.4-48M\/ano em Lista C5 sist\u00eamica.<\/p>\n

A ECP + TSEBT + TMO: o est\u00e1gio refrat\u00e1rio avan\u00e7ado<\/h2>\n

A terceira camada \u00e9 o refrat\u00e1rio. Padr\u00e3o setorial inclui (a) ECP Extracorporeal Photopheresis<\/strong> Therakos CELLEX Mallinckrodt apheresis kit R$ 4-8k\/sess\u00e3o + 8-MOP psoraleno + UVA c\u00e2mara \u00d7 24-50 sess\u00f5es\/ano para SS + DLBCL refrat\u00e1rio; (b) TSEBT Total Skin Electron Beam Therapy<\/strong> Varian Clinac iX \/ TrueBeam STx 30-36Gy whole-skin com filtro el\u00e9trons; (c) TMO aut\u00f3logo + alog\u00eanico<\/strong> para SS muito avan\u00e7ado refrat\u00e1rio com REDOME + REREME + criopreserva\u00e7\u00e3o CryoStor + N2; (d) CAR-T cell em desenvolvimento cl\u00ednico<\/strong> para CTCL com targets CD30\/CD7; (e) livro RBI ECP + TSEBT + TMO<\/strong> com reten\u00e7\u00e3o 10 anos.<\/p>\n

Hospital com 8-25 SS refrat\u00e1rios \u00d7 ECP 24 sess\u00f5es \u00d7 R$ 6k = R$ 1.15-3.6M\/ano em ECP + 5-15 TSEBTs\/ano + livro RBI.<\/p>\n

Tr\u00eas perfis de PGRSS para linfoma cut\u00e2neo<\/h2>\n

PGRSS gen\u00e9rico subdimensionado.<\/strong> Sem cobertura espec\u00edfica para Lista C5 + ADC + ECP + TSEBT. Custo mensal R$ 9.000-20.000<\/strong>, efic\u00e1cia limitada.<\/p>\n

PGRSS dedicado intermedi\u00e1rio.<\/strong> Cobertura para PUVA + sist\u00eamica b\u00e1sica, sem brentuximab + mogamulizumab + ECP + TSEBT. Custo mensal R$ 20.000-35.000<\/strong>, efic\u00e1cia 100-200%.<\/p>\n

PGRSS dedicado completo linfoma cut\u00e2neo.<\/strong> PUVA + Valchlor + Adcetris + Poteligeo + ECP + TSEBT + TMO + integra\u00e7\u00e3o com PGRSS de hemato onc<\/a>. Custo mensal R$ 35.000-52.000<\/strong>, ROI 250-500%.<\/p>\n

Os tr\u00eas erros que aparecem em PGRSS linfoma cut\u00e2neo subdimensionado<\/h2>\n

O primeiro \u00e9 o subdimensionamento de Valchlor mecloretamina t\u00f3pico<\/strong>. Lista C5 com cofre + descarte espec\u00edfico citost\u00e1tico + EPI + treinamento paciente.<\/p>\n

O segundo \u00e9 a aus\u00eancia de Lista C5 brentuximab + mogamulizumab<\/strong>. Adcetris + Poteligeo R$ 25-65k\/dose com cofre + cadeia fria + livro 344 + REMS.<\/p>\n

O terceiro \u00e9 a descarte de TSEBT acelerador linear como Grupo D<\/strong>. Varian Clinac iX + TrueBeam STx fim de vida 8-12 anos = RAEE m\u00e9dico CNEN obrigat\u00f3rio.<\/p>\n

A regula\u00e7\u00e3o de PGRSS no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com linfoma cut\u00e2neo como prioridade. As institui\u00e7\u00f5es que estruturam PGRSS dedicado desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A SBD Sociedade Brasileira de Dermatologia<\/a> \u00e9 refer\u00eancia t\u00e9cnica.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS de linfoma cut\u00e2neo<\/a><\/strong> \u2014 cap\u00edtulo dedicado a CTCL micose fungoide+SS+CD30+ALCL+CBCL, skin-directed PUVA+UVB-NB+Valchlor mecloretamina+bexaroteno Targretin, sist\u00eamica vorinostat Zolinza+romidepsin Istodax+brentuximab Adcetris+mogamulizumab Poteligeo+alemtuzumab Campath, ECP Therakos CELLEX + TSEBT Varian + TMO REDOME.<\/p>\n","protected":false},"excerpt":{"rendered":"

Linfoma cut\u00e2neo gera RSS espec\u00edfico \u2014 CTCL, micose fungoide, CAR-T. PGRSS dedicado.<\/p>\n","protected":false},"author":3,"featured_media":2152,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2366,2980,2979,2981],"class_list":["post-2153","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-car-t","tag-ctcl","tag-linfoma-cutaneo","tag-micose-fungoide"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2153"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2153\/revisions"}],"predecessor-version":[{"id":4301,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2153\/revisions\/4301"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2152"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}